Venous thromboembolism risk and management in women with cancer and thrombophilia

Gender Medicine

Volumn 2, Issue SUPPL. A, 2005, Pages

  Prandoni, Paolo ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Cancer; Risk factors; Thrombophilia; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; AROMATASE INHIBITOR; DALTEPARIN; ENOXAPARIN; ESTROGEN; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROGESTERONE; TAMOXIFEN; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULATION; BLEEDING; BREAST CANCER; CANCER; CANCER STAGING; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG HALF LIFE; FEMALE; HIGH RISK PATIENT; HUMAN; IMMOBILIZATION; INFORMATION RETRIEVAL; LONG TERM CARE; LUNG EMBOLISM; MEDLINE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SCISEARCH; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; THROMBOPHILIA; TREATMENT OUTCOME; VEIN THROMBOSIS; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

EID: 33645033455     PISSN: 15508579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1550-8579(05)80062-2     Document Type: Article

References (48)

1. Heit JA Silverstein MD Mohr DN et. al. Predictors of survival after deep vein thrombosis and pulmonary embolism: A population-based, cohort study Arch Intern Med. 159 1999 445-453
2. Turpie AG Management of venous thromboembolism: Optimization by clinical trials Haemostasis 26 Suppl 4 1996 220-226
3. Rickles FR Levine M Edwards RL Hemostatic alterations in cancer patients Cancer Metastasis Rev. 11 1992 237-248
4. Green KB Silverstein RL Hypercoagulability in cancer Hematol Oncol Clin North Am. 10 1996 499-530
5. Lieberman JS Borrero J Urdaneta E Wright IS Thrombophlebitis and cancer JAMA 177 1961 542-545
6. Mandala M Ferretti G Cremonesi M et. al. Venous thromboembolism and cancer: New issues for an old topic Crit Rev Oncol Hematol 48 2003 65-80
7. Geerts W Pineo GF Heit GA et. al. Prevention of venous thromboembolism Chest 126 2004 338S-400S
8. Peuscher FW Thrombosis and bleeding in cancer patients Neth J Med. 24 1981 23-35
9. Thompson CM Rodgers RL Analysis of the autopsy records of 157 cases of carcinoma of the pancreas with particular reference to the incidence of thromboembolism Am J Med Sci 223 1952 469-476
10. Falanga A Zacharski L Deep vein thrombosis in cancer: The scale of the problem and approaches to management Ann Oncol. 16 2005 696-701
11. Elting LS Escalante CP Cooksley C et. al. Outcomes and cost of deep venous thrombosis among patients with cancer Arch Intern Med. 164 2004 1653-1661
12. Tateo S Mereu L Salamano S et. al. Ovarian cancer and venous thromboembolic risk Gynecol Oncol. 99 2005 119-125
13. Prandoni P Falanga A Piccioli A Cancer and venous thromboembolism Lancet Oncol. 6 2005 401-410
14. Sorensen HT Mellemkjaer L Olsen JH Baron JA Prognosis of cancers associated with venous thromboembolism N Engl J Med. 343 2000 1846-1850
15. Zotz RB Gerhard A Scharf RE Inherited thrombophilia and gestational venous thromboembolism Best Pract Res Clin Haematol. 16 2003 243-259
16. Minnema MC Janssen HL Niermeijer P de Man RA Budd-Chiari syndrome: Combination of genetic defects and the use of oral contraceptive leading to hypercoagulability J Hepatol 33 2000 509-512
17. Simioni P The molecular genetics of familial venous thrombosis Baillieres Best Pract Res Clin Haematol 12 1999 479-503
18. Laffan M Tuddenham E Thrombophilia: An expanding group of genetic defects that predispose to thrombosis Mol Med Today 3 1997 303-309
19. Blom JW Doggen CJ Osanto S Rosendaal FR Malignancies, prothrombotic mutations, and the risk of venous thrombosis JAMA 293 2005 715-722
20. Merli G Anticoagulants in the treatment of deep vein thrombosis Am J Med 118 Suppl 8A 2005 13S-20S
21. Romero A Alonso C Rincon M et. al. Risk of venous thromboembolic disease in women: A qualitative systematic review Eur J Obstet Gynecol Reprod Biol. 121 2005 8-17
22. Sallah S Wan JY Nguyen NP Venous thrombosis in patients with solid tumors: Determination of frequency and characteristics Thromb Haemost 87 2002 575-579
23. Otten HM Mathijssen J ten Cate H et. al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: An underestimated phenomenon Arch Intern Med. 164 2004 190-194
24. Morgan MA Iyengar TD Napiorkowski BE et. al. The clinical course of deep vein thrombosis in patients with gynecologic cancer Gynecol Oncol 84 2002 67-71
25. for the MEODENOX Study Alkhan R Cohen AT Combe S et. al. Risk factors for venous thromboembolism in hospitalized patients with acute medial illness: Analysis of the MEDENOX Study Arch Intern Med. 164 2004 963-968
26. Heit JA Silverstein MD Mohr DN et. al. The epidemiology of venous thromboembolism in the community Thromb Haemost 86 2001 452-463
27. Heit JA Mohr DN Silverstein MD et. al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: A population-based cohort study Arch Intern Med 160 2000 761-768
28. Hansson PO Sorbo J Eriksson H Recurrent venous thromboembolism after deep vein thrombosis: Incidence and risk factors Arch Intern Med 160 2000 769-774
29. Saphner T Tormey DC Gray R Venous and arterial thrombosis in patients with received adjuvant therapy for breast cancer J Clin Oncol 9 1991 286-294
30. Abstract Cushman M Costantino JP Bovill EG et. al. Effect of tamoxifen on venous thrombosis risk factors in women without cancer: The Breast Cancer Prevention Trial Br J Haematol 120 2003 109-116
31. Decensi A Maisonneuve P Rotmensz N et. al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial Circulation 111 2005 650-656
32. Goldhaber SZ Tamoxifen: Preventing breast cancer and placing the risk of deep vein thrombosis in perspective Circulation 111 2005 539-541
33. Fisher B Costantino JP Wickerham DL et. al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst. 90 1998 1371-1388
34. Levine MN Gent M Hirsh J et. al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer N Engl J Med 318 1988 404-407
35. for the National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group Prichard KI Paterson AH Paul NA et. al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer J Clin Oncol 14 1996 2731-2737
36. for the Armidx Writing Committee and the Investigators Committee Members Bonneterre J Buzdar A Nabholtz JM et. al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma Cancer 92 2001 2247-2258
37. Coombes RC Hall E Gibson LJ et. al. A randomized trial of exemestane after two three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 2004 1081-1092
38. Buller HR Agnelli G Hull RD et. al. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 401S-428S [published correction appears in Chest. 2005; 127:416]
39. for the Matisse Investigators Buller HR Davidson BL Decousus H et. al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism [published correction appears in N Engl J Med. 2004;350:423] N Engl J Med 349 2003 1695-1702
40. for the Matisse Investigators Buller HR Davidson BL Decousus H et. al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: A randomized trial Ann Intern Med 140 2004 867-873
41. Kam PC Kaur N Thong CL Direct thrombin inhibitors: Pharmacology and clinical relevance Anaesthesia 60 2005 565-574
42. Parandoni P Lensing AW Cogo A et. al. The longterm clinical course of acute deep venous thrombosis Ann Intern Med 125 1996 1-7
43. for the Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators Lee AY Levine MN Baker RI et. al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer N Engl J Med 349 2003 146-153
44. [published correction appears in N Engl J Med. 1999;341:298] Kearon C Genet M Hirsh J et. al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism N Engl J Med 340 1999 901-907
45. for the Duration of Anticoagulation Trial Study Group Schulman S Rhedin AS Lindmarker P et. al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism N Engl J Med 332 1995 1661-1665
46. Kakkar AK Levine MN Kadziola Z et. al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS) J Clin Oncol 22 2004 1944-1948
47. Klerk CP Smorenburg SM Otten HM et. al. The effect of low molecular weight heparin on survival in patients with advanced malignancy J Clin Oncol 23 2005 2130-2135
48. Altinbas M Coskun HS Er O et. al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer J Thromb Haemost 2 2004 1266-1271